WeVote
Log In

Bill

Bill

S 350

Prohibits substance use disorder treatment providers from using deceptive marketing practices.

2026-2027 Regular Session Introduced by Brian Stack and 1 co-sponsor

New Jersey bill prohibits substance use disorder treatment providers from using deceptive marketing to protect vulnerable patients seeking addiction treatment services.

Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
0
WeVote Research Nonpartisan
Bill Summary · S 350

Legislative bill overview

S 350 establishes legal prohibitions against deceptive marketing practices by substance use disorder (SUD) treatment providers in New Jersey. The bill aims to protect vulnerable individuals seeking treatment by regulating how treatment facilities advertise their services and qualifications.

Why is this important

The SUD treatment industry has faced widespread criticism for predatory marketing targeting desperate patients and families, including false claims about success rates, insurance coverage, and staff credentials. Unregulated marketing in this sector can delay appropriate treatment, drain financial resources, and erode trust in legitimate providers. Clear legal standards could protect both patients and reputable treatment facilities operating honestly.

Potential points of contention

  • Defining "deceptive": The bill's enforceability depends heavily on specific definitions of what constitutes deceptive marketing—vague language could lead to inconsistent application or legal challenges
  • Compliance costs: Small treatment providers may face administrative burdens and legal costs to ensure marketing compliance, potentially affecting competition and service availability
  • Enforcement mechanisms: The bill's effectiveness relies on adequate state oversight and investigation resources; without clear enforcement authority and funding, violations may go unaddressed
  • Free speech concerns: Some providers may argue restrictions on marketing claims implicate First Amendment protections, particularly around subjective claims about treatment quality

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.